US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Prescription Drugs: market research reports

RSS Feeds

Prescription Drugs market research reports and industry analysis

  2    4  5  6  7  8  9  10  
Iran Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... the rial means thatwe expect the value of the market in US dollar terms to contract sharply. On a positive note, improvedinternational relations have reduced the political risk associated with operating in the market formultinational ...  |  read more...
$1,295.00
Israel Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... need for specialtytreatments, thereby capitalising on the country's strong academic research infrastructure. Favourablefactors include high per capita spending on medicines, a market size approaching US$2bn, a highproportion of pensioners and a largely urbanised population. However, ...  |  read more...
$1,295.00
Kuwait Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... thoroughlyscrutinised. New hospitals are being planned for expatriate workers and infrastructure development willcontinue to be a key area of growth, in addition to opportunities for private healthcare insurance providersto serve the expatriate market. The government's ...  |  read more...
$1,295.00
Malaysia Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... country's private healthcare sector is attracting foreign investment and development, whichsupports the growing medical tourism market. However, the shortage of specialist medical staff and thesignificant presence of counterfeit drugs are issues the country must overcome ...  |  read more...
$1,295.00
Portugal Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... consumer spending. Thehealthcare budget will continue to be slashed in 2014; the authorities have to make further cuts inreimbursement; and reference prices are continually pushed downwards. The few opportunities for growthare being taken by manufactures ...  |  read more...
$1,295.00
Bangladesh Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... -pocket -highlighting the low affordability of high-value pharmaceuticals and sophisticated healthcare treatments. Headline Expenditure Projections Pharmaceuticals: BDT138.81bn (US$1.78bn) in 2013 to BDT154.74bn (US$1.99bn) in 2014; +11.5%in local currency terms and +12.1% in US dollar terms ...  |  read more...
$1,295.00
France Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... in the healthcare system.However, we question the strength of this legislation, as development and manufacturing costs for theseproducts are high and therefore actual cost savings secured through biosimilars may ultimately be limited. Furthermore, ongoing safety ...  |  read more...
$1,295.00
Peru Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... companies can generate rapid sales growth due to the lack of mandatory medicine pricingsystem in Peru. More stringent quality controls, relatively weak domestic pharmaceutical industry, ongoingliberalisation of bilateral trade agreements and the recognition of 'High ...  |  read more...
$1,295.00
Uganda Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... will beslow due to the limited capabilities of local pharmaceutical companies, which are unable to compete withthe greater range of medicines made by multinational generic drugmakers. Headline Expenditure Projections Pharmaceuticals: UGX824.35bn (US$320mn) in 2013 to ...  |  read more...
$1,295.00
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... lack ofaccess to medical treatment has led to a large proportion of the population becoming more reliant onherbal and traditional medicine, which has seen a recent influx in the country. However, with theZimbabwean authorities pushing ...  |  read more...
$1,295.00
Belgium Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... multinational firms. Even though per capitaspending on pharmaceuticals is relatively high, it is subjected to continual downward pressure - creatingopportunities for growth for manufacturers of generic drugs. In other words, economic agendas mean thatthe government ...  |  read more...
$1,295.00
Philippines Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... medicines, account for46% of the total medical out-of-pocket expenses of Philippine households. For poorer people, thispercentage goes up to 55%. However, out-of-pocket financing for healthcare indicates inequality. As theHaiyan tragedy in November 2013 revealed, many ...  |  read more...
$1,295.00
Singapore Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... with the government's promise to improve healthcare affordability are other growth opportunitiesfor pharmaceutical firms. However, its long-term growth potential will continue to be limited by its smallpopulation. Headline Expenditure Projections Pharmaceuticals: SGD990mn (US$790mn) in 2013 ...  |  read more...
$1,295.00
Ukraine Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... business environmentand capital outflow restrictions. Exchange rate risks present considerable downside to drugmakers'revenues in the country, and with the threat of price controls and compulsory licensing, Ukraine's Risk/Reward ratio is worsening. Over the long term, ...  |  read more...
$1,295.00
Canada Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... Althoughdrugmakers will continue to face generic competition and drug pricing pressure in the country, improvinghealthcare coverage and broader drug reimbursement lists will increase patients' access to medicines andprovide revenue-generating opportunities for drugmakers. Headline Expenditure Projections ...  |  read more...
$1,295.00
Kazakhstan Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... market asdemand for medicines is driven by private consumption. Nevertheless, we expect pharmaceutical spendingto accelerate as the government commits to increasing healthcare expenditure and wages continue to grow. For multinational drug manufactures, Kazakhstan will continue ...  |  read more...
$1,295.00
Romania Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... Unemployment levels and the state of Romania's economy directly impact revenuesfor the state insurer; while the country's economic picture in early 2014 is improving, the benefits will notbe felt until the medium term. These issues ...  |  read more...
$1,295.00
United States Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... from drugmakers, but this did not materialise in a meaningful sense, primarily due to industrycooperation when the legislation was being drafted. Of greater near-term concern to pharmaceuticalcompanies is the shifting pricing and reimbursement landscape globally. ...  |  read more...
$1,295.00
Estonia Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... wholesale prices, in line with our forecast for a slowdown in sales growth in 2013. Growth inpharmaceutical spending in Estonia will continue to be held back as the Estonian government's policy offiscal restraint continues. Estonia ...  |  read more...
$1,295.00
Myanmar Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... is to realise its ambitious public health insurance scheme. Political uncertainties dueto the upcoming election in 2015 may also deter investors in the short term. Headline Expenditure Projections Pharmaceuticals: MMK324.8bn (US$350mn) in 2013 to MMK387.5bn ...  |  read more...
$1,295.00
Puerto Rico Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
... globalpharmaceutical production hub by offering incentives for the expansion of existing manufacturing plantsand pursuing new opportunities in contract manufacturing operations as well as generic and biologic drugproduction. However, it will be difficult for the island ...  |  read more...
$1,295.00
Romania Pharmaceutical Report - Q4, 2013
3/3/2014 | published by: Intellinews
... market dropped in RON terms for the first time in the past seven years, according to our calculations based on available statistics. The pharmaceutical sales also dropped by 3.6% y/y in volume terms and as ...  |  read more...
$475.00
Analyzing the Global Diabetes Market
3/1/2014 | published by: Aruvian's R'search
... diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were ...  |  read more...
$1,000.00
UAE Healthcare Sector Outlook 2018
3/1/2014 | published by: RNCOS
... diseases have given a push to the healthcare sector. Government has laid down various policies and measures to improvise the standard of healthcare services in the country. The recent years have seen emergence of various ...  |  read more...
$1,200.00
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
$3,495.00
  2    4  5  6  7  8  9  10  
 
Our Clients